HK Stock Market Move | ENN ENERGY (02688) rose nearly 4% in morning trading; Hong Kong city gas PB is at a historical low, and institutions are bullish on stronger dividend payouts.
ENN ENERGY (02688) rose nearly 4% in morning trading. As of press time, it was up 3.67% at HK$51.65, with a turnover of HK$78.286 million.
ENN ENERGY (02688) rose nearly 4% in morning trading. As of press time, it was up 3.67% at HK$51.65, with a turnover of HK$78.286 million.
On the news front, ENN ENERGY recently announced that in the first three quarters of 2026, the Group recorded natural gas retail sales volume of 19.23 billion cubic meters, up 0.2% year on year. Among this, gas sales to industrial and commercial users rose 0.4% year on year to 15.273 billion cubic meters, while residential gas sales volume rose 1.4% year on year to 3.856 billion cubic meters.
Shenwan Hongyuan Group said in a research report that the PB of Hong Kong-listed city gas companies is at a historical low. The brokerage noted that the earnings stability of Hong Kong-listed city gas companies has strengthened somewhat, the marginal impact of connections continues to weaken, emerging businesses are gradually contributing incremental earnings, and combined with declining capital expenditure, companies' dividend payouts are expected to increase. The brokerage noted that demand is under short-term pressure, but there remains broad long-term development space after costs fall back.
Related Articles

China Securities Co., Ltd.: Electronics sector continues high growth; semiconductor localization expected to accelerate

HK Stock Market Move | |3D MEDICINES (01244) Surges Over 14%; Partner SELLAS' Cancer Vaccine GPS Succeeds in Phase III AML Trial

CLSA: Raises BEKE-W (02423) target price to HK$67, reiterates "outperform" rating
China Securities Co., Ltd.: Electronics sector continues high growth; semiconductor localization expected to accelerate

HK Stock Market Move | |3D MEDICINES (01244) Surges Over 14%; Partner SELLAS' Cancer Vaccine GPS Succeeds in Phase III AML Trial

CLSA: Raises BEKE-W (02423) target price to HK$67, reiterates "outperform" rating






